secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2024-01-18T23:59:59+00:00
Accession:  0000950170-24-005198
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen discontinues SZN-1326; SZN-043 Phase 1a complete, data due Q1 2024
---------------------------------------------------------------------------

- SZN-043 Phase 1a enrollment in chronic liver disease and healthy volunteers complete; safety/pharmacodynamic data expected Q1 2024.
- Phase 1b for alcohol-associated hepatitis to initiate soon; proof-of-concept data possible in H2 2024.
- SZN-1326 development in IBD discontinued due to asymptomatic grade 3 ALT/AST elevations at high doses and strategic factors.
- No serious adverse events in SZN-1326 trial; transaminase elevations resolved spontaneously in all subjects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017024005198/0000950170-24-005198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017024005198/srzn-20240118.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-005198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer